HRP20020541B1 - Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors - Google Patents
Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitorsInfo
- Publication number
- HRP20020541B1 HRP20020541B1 HR20020541A HRP20020541A HRP20020541B1 HR P20020541 B1 HRP20020541 B1 HR P20020541B1 HR 20020541 A HR20020541 A HR 20020541A HR P20020541 A HRP20020541 A HR P20020541A HR P20020541 B1 HRP20020541 B1 HR P20020541B1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclic amp
- phosphodiesterase inhibitors
- group
- pyrrolidine derivatives
- specific phosphodiesterase
- Prior art date
Links
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 title 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 229940095074 cyclic amp Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- -1 polycyclic hydrocarbons Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/471,846 US6258833B1 (en) | 1999-12-23 | 1999-12-23 | Cyclic AMP-specific phosphodiesterase inhibitors |
PCT/US2000/032401 WO2001047905A1 (en) | 1999-12-23 | 2000-11-28 | Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20020541A2 HRP20020541A2 (en) | 2004-08-31 |
HRP20020541B1 true HRP20020541B1 (en) | 2008-06-30 |
Family
ID=23873210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020541A HRP20020541B1 (en) | 1999-12-23 | 2002-06-20 | Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
Country Status (29)
Country | Link |
---|---|
US (6) | US6258833B1 (ja) |
EP (1) | EP1242400B1 (ja) |
JP (1) | JP4294903B2 (ja) |
KR (1) | KR20020063600A (ja) |
CN (1) | CN1434813A (ja) |
AT (1) | ATE325108T1 (ja) |
AU (1) | AU778543B2 (ja) |
BG (1) | BG65892B1 (ja) |
BR (1) | BRPI0016693B1 (ja) |
CA (1) | CA2395193C (ja) |
CZ (1) | CZ20022188A3 (ja) |
DE (1) | DE60027769D1 (ja) |
EA (1) | EA005686B1 (ja) |
EE (1) | EE05087B1 (ja) |
GE (1) | GEP20043384B (ja) |
HK (1) | HK1051359A1 (ja) |
HR (1) | HRP20020541B1 (ja) |
HU (1) | HUP0301113A3 (ja) |
IL (1) | IL150313A0 (ja) |
IS (1) | IS6436A (ja) |
MX (1) | MXPA02006212A (ja) |
NO (1) | NO20023008L (ja) |
PL (1) | PL202227B1 (ja) |
RS (1) | RS50841B (ja) |
SK (1) | SK287964B6 (ja) |
TR (1) | TR200400702T4 (ja) |
UA (1) | UA73964C2 (ja) |
WO (1) | WO2001047905A1 (ja) |
ZA (1) | ZA200205551B (ja) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455571B1 (en) * | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US20010049368A1 (en) * | 2000-02-29 | 2001-12-06 | Reines Scott A. | Method for treating or preventing depression |
WO2002002500A1 (en) * | 2000-07-03 | 2002-01-10 | Speedel Pharma Ag | Preparation of (r)-2-alkyl-3-phenylpropionic acids |
US6953774B2 (en) * | 2000-08-11 | 2005-10-11 | Applied Research Systems Ars Holding N.V. | Methods of inducing ovulation |
WO2002047540A2 (en) * | 2000-12-15 | 2002-06-20 | The General Hospital Corporation | Methods for inhibiting fibrosis |
US20040014099A1 (en) * | 2001-03-19 | 2004-01-22 | Decode Genetics Ehf. | Susceptibility gene for human stroke; methods of treatment |
US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
KR100951218B1 (ko) | 2001-10-16 | 2010-04-05 | 메모리 파마슈티칼스 코포레이션 | 신경계 증후군의 치료를 위한 pde-4 억제제로서의4-(4-알콕시-3-히드록시페닐)-2-피롤리돈 유도체 |
KR101056916B1 (ko) | 2001-12-14 | 2011-08-12 | 라보라토리스 세로노 에스.에이. | 비폴리펩티드 고리에이엠피 레벨 모듈레이터를 이용한 배란유도 방법 |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
DE10228132A1 (de) * | 2002-06-24 | 2004-01-22 | Arzneimittelwerk Dresden Gmbh | Amide cyclischer Aminosäuren als PDE 4 Inhibitoren |
PL1606261T3 (pl) | 2003-03-10 | 2010-04-30 | Astrazeneca Ab | Nowy sposób przygotowania roflumilastu |
CN1805929A (zh) * | 2003-04-16 | 2006-07-19 | 记忆药物公司 | 磷酸二酯酶4抑制剂 |
AU2004232973A1 (en) * | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
WO2005000247A2 (en) * | 2003-06-25 | 2005-01-06 | Smithkline Beecham Corporation | 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |
EP1670476A4 (en) * | 2003-09-30 | 2009-05-27 | Merck & Co Inc | ANTAGONISTS OF TACHYKININ RECEPTOR BASED ON PHENYL PYRROLIDINE ETHER |
US20050201989A1 (en) * | 2004-02-19 | 2005-09-15 | St. Camillus Medical, Inc. | Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitors of tumor necrosis factor-alpha |
ES2317223T3 (es) * | 2004-04-08 | 2009-04-16 | Wyeth | Derivados de tioamida como moduladores del receptor de progesterona. |
US7432266B2 (en) * | 2004-10-15 | 2008-10-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
US7585882B2 (en) * | 2004-10-20 | 2009-09-08 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
ES2421916T3 (es) * | 2005-03-16 | 2013-09-06 | Nycomed Gmbh | Forma farmacéutica de sabor enmascarado que contiene roflumilast |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
CN101355876B (zh) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | 一种适用于眼部给药的组合物 |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (en) * | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
CA2663347A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | Ppar mediated modulation of neurogenesis |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US20100210633A1 (en) * | 2006-10-12 | 2010-08-19 | Epix Delaware, Inc. | Carboxamide compounds and their use |
DK2176220T3 (da) | 2007-08-07 | 2013-06-10 | Takeda Pharmaceutical | Pyrrolidin-2-on-derivater som androgenreceptormodulatorer. |
JP2011506466A (ja) | 2007-12-11 | 2011-03-03 | 株式会社サイトパスファインダー | カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用 |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102603623A (zh) * | 2011-12-26 | 2012-07-25 | 北京赛林泰医药技术有限公司 | 制备高纯度罗氟司特的方法 |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
JO3264B1 (ar) * | 2013-03-13 | 2018-09-16 | Lilly Co Eli | مركبات ازيتيدينيل أوكسي فينيل بيروليدين |
ES2733552T3 (es) * | 2014-01-24 | 2019-11-29 | Celgene Corp | Procedimientos para el tratamiento de la obesidad mediante apremilast |
HUE052714T2 (hu) * | 2014-05-29 | 2021-05-28 | Mitsubishi Tanabe Pharma Corp | Új pirrolidin vegyület és alkalmazás melanokortin receptor agonistaként |
WO2016033776A1 (en) * | 2014-09-04 | 2016-03-10 | Eli Lilly And Company | Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol |
AR101696A1 (es) | 2014-09-12 | 2017-01-04 | Lilly Co Eli | Compuestos de azetidiniloxifenilpirrolidina |
WO2017072796A1 (en) | 2015-10-30 | 2017-05-04 | Council Of Scientific & Industrial Research | 2-pyridone based compounds useful as potential phosphodiesterase3a (pde3a)inhibitors and a process for the preparation thereof |
JP6392297B2 (ja) * | 2015-11-27 | 2018-09-19 | 田辺三菱製薬株式会社 | 医薬組成物 |
CN111094270B (zh) | 2017-09-29 | 2023-09-22 | 田边三菱制药株式会社 | 光学活性吡咯烷化合物及其制造方法 |
CA3123995C (en) * | 2018-12-18 | 2023-05-23 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Phenylpyrrolidine compound and use thereof |
CN112409333A (zh) * | 2019-08-23 | 2021-02-26 | 湖北生物医药产业技术研究院有限公司 | 苯基吡咯烷类化合物 |
TW202146385A (zh) * | 2020-04-29 | 2021-12-16 | 大陸商廣東東陽光藥業有限公司 | 取代的吡咯烷類化合物及其在藥物中的應用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5821622B2 (ja) * | 1973-02-28 | 1983-05-02 | ウェルファイド株式会社 | ピロリジンメタノ−ル ノ セイゾウホウ |
JPS50108258A (ja) * | 1974-02-08 | 1975-08-26 | ||
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
JPH07300455A (ja) * | 1994-03-08 | 1995-11-14 | Mitsubishi Chem Corp | 3−フェニルピロリジン誘導体 |
CA2143143A1 (en) * | 1994-03-08 | 1995-09-09 | Toshihiko Tanaka | 3-phenylpyrrolidine derivatives |
US5998428A (en) | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
US5856103A (en) * | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
DE19601938A1 (de) * | 1996-01-12 | 1997-07-17 | Schering Ag | Neue Phosphodiesteraseinhibitoren |
ID22781A (id) * | 1997-04-04 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan nikotinamida |
US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
-
1999
- 1999-12-23 US US09/471,846 patent/US6258833B1/en not_active Expired - Lifetime
-
2000
- 2000-11-21 US US09/717,956 patent/US6423710B1/en not_active Expired - Lifetime
- 2000-11-28 BR BRPI0016693-6A patent/BRPI0016693B1/pt not_active IP Right Cessation
- 2000-11-28 EE EEP200200351A patent/EE05087B1/xx not_active IP Right Cessation
- 2000-11-28 TR TR2004/00702T patent/TR200400702T4/xx unknown
- 2000-11-28 JP JP2001549376A patent/JP4294903B2/ja not_active Expired - Fee Related
- 2000-11-28 EA EA200200590A patent/EA005686B1/ru not_active IP Right Cessation
- 2000-11-28 CZ CZ20022188A patent/CZ20022188A3/cs unknown
- 2000-11-28 RS YUP-480/02A patent/RS50841B/sr unknown
- 2000-11-28 AU AU24262/01A patent/AU778543B2/en not_active Ceased
- 2000-11-28 EP EP00987999A patent/EP1242400B1/en not_active Expired - Lifetime
- 2000-11-28 WO PCT/US2000/032401 patent/WO2001047905A1/en active IP Right Grant
- 2000-11-28 UA UA2002065192A patent/UA73964C2/uk unknown
- 2000-11-28 IL IL15031300A patent/IL150313A0/xx unknown
- 2000-11-28 PL PL355988A patent/PL202227B1/pl unknown
- 2000-11-28 MX MXPA02006212A patent/MXPA02006212A/es active IP Right Grant
- 2000-11-28 CN CN00819096A patent/CN1434813A/zh active Pending
- 2000-11-28 KR KR1020027008133A patent/KR20020063600A/ko not_active Application Discontinuation
- 2000-11-28 AT AT00987999T patent/ATE325108T1/de not_active IP Right Cessation
- 2000-11-28 DE DE60027769T patent/DE60027769D1/de not_active Expired - Lifetime
- 2000-11-28 SK SK917-2002A patent/SK287964B6/sk not_active IP Right Cessation
- 2000-11-28 GE GE4860A patent/GEP20043384B/en unknown
- 2000-11-28 CA CA002395193A patent/CA2395193C/en not_active Expired - Fee Related
- 2000-11-28 HU HU0301113A patent/HUP0301113A3/hu unknown
-
2001
- 2001-05-02 US US09/847,424 patent/US6458787B1/en not_active Expired - Lifetime
-
2002
- 2002-05-17 US US10/151,202 patent/US6716871B2/en not_active Expired - Lifetime
- 2002-06-19 IS IS6436A patent/IS6436A/is unknown
- 2002-06-20 HR HR20020541A patent/HRP20020541B1/xx not_active IP Right Cessation
- 2002-06-21 NO NO20023008A patent/NO20023008L/no unknown
- 2002-06-24 BG BG106860A patent/BG65892B1/bg unknown
- 2002-07-11 ZA ZA200205551A patent/ZA200205551B/en unknown
-
2003
- 2003-03-19 HK HK03102027.0A patent/HK1051359A1/zh unknown
-
2004
- 2004-01-15 US US10/758,675 patent/US6998416B2/en not_active Expired - Lifetime
-
2005
- 2005-11-07 US US11/268,374 patent/US7176229B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020541B1 (en) | Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors | |
ES2123858T3 (es) | Derivados de amidas ciclicas. | |
ATE214055T1 (de) | Retinoid-potenzierende verbindungen | |
ATE184194T1 (de) | Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)- homoserinlacton | |
DK249089A (da) | Benzamid-forbindelser, der er nyttige som protease-inhibitorer | |
ES2177058T3 (es) | Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p. | |
TW240227B (ja) | ||
MX9301045A (es) | Procedimiento para preparar antagonistas receptores de fibrinogeno. | |
FI940731A (fi) | Amiditetratsolit ACAT-inhibiitoreina | |
BR0107823A (pt) | Processo para a obtenção de ácido fórmico anidro ou substancialmente anidro, uso de uma carboxamida, e, aparelho para realizar um processo | |
ATE168679T1 (de) | Neue tetracyclische verbindungen | |
EA200101209A1 (ru) | Новые производные бензола, способ их получения и фармацевтические композиции, содержащие их | |
DE69017774D1 (de) | Benzothiazol-derivate als fungizide. | |
ATE357447T1 (de) | Inhibitoren des papilloma-virus | |
YU74501A (sh) | Sinteza 3-amino-3-aril propionata | |
ATE255111T1 (de) | Abeo-ergolinderivate als 5ht1a liganden | |
CA2012514A1 (en) | Stabilizers derived from n-hydroxy hindered amines by michael addition reactions | |
TH14957EX (th) | สารประกอบชนิดใหม่ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20151124 Year of fee payment: 16 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20161128 |